Short Interest in abrdn Life Sciences Investors (NYSE:HQL) Decreases By 37.6%

abrdn Life Sciences Investors (NYSE:HQL) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 18,752 shares, a decline of 37.6% from the February 12th total of 30,034 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 129,078 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 129,078 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company’s shares are sold short.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several institutional investors have recently made changes to their positions in HQL. Penserra Capital Management LLC grew its holdings in abrdn Life Sciences Investors by 3.2% during the 3rd quarter. Penserra Capital Management LLC now owns 794,138 shares of the company’s stock valued at $12,317,000 after purchasing an additional 24,481 shares during the last quarter. LPL Financial LLC lifted its stake in abrdn Life Sciences Investors by 20.0% in the fourth quarter. LPL Financial LLC now owns 448,846 shares of the company’s stock worth $7,532,000 after purchasing an additional 74,787 shares during the last quarter. Raymond James Financial Inc. lifted its stake in abrdn Life Sciences Investors by 12.5% in the third quarter. Raymond James Financial Inc. now owns 423,031 shares of the company’s stock worth $6,561,000 after purchasing an additional 47,071 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in shares of abrdn Life Sciences Investors by 1.8% during the fourth quarter. Flagship Harbor Advisors LLC now owns 363,381 shares of the company’s stock valued at $6,098,000 after buying an additional 6,257 shares during the period. Finally, Wolverine Asset Management LLC boosted its position in shares of abrdn Life Sciences Investors by 50.8% during the third quarter. Wolverine Asset Management LLC now owns 215,521 shares of the company’s stock valued at $3,343,000 after buying an additional 72,601 shares during the period. Institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Stock Performance

NYSE:HQL traded down $0.25 during midday trading on Friday, hitting $16.38. 45,788 shares of the company traded hands, compared to its average volume of 124,613. The firm’s fifty day moving average is $16.80 and its 200-day moving average is $16.38. abrdn Life Sciences Investors has a 12-month low of $10.55 and a 12-month high of $17.80.

abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Friday, February 20th will be given a dividend of $0.56 per share. This represents a $2.24 dividend on an annualized basis and a yield of 13.7%. This is a positive change from abrdn Life Sciences Investors’s previous quarterly dividend of $0.50. The ex-dividend date is Friday, February 20th.

About abrdn Life Sciences Investors

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.